Related Experiment Video
Updated: Feb 3, 2026

Generation of Enterobacter sp. YSU Auxotrophs Using Transposon Mutagenesis
Published on: October 31, 2014
Transposon mutagenesis screen in mice identifies TM9SF2 as a novel colorectal cancer oncogene
Christopher R Clark1, Makayla Maile1, Patrick Blaney1
1Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, MN, USA.
Abstract:
New therapeutic targets for advanced colorectal cancer (CRC) are critically needed. Our laboratory recently performed an insertional mutagenesis screen in mice to identify novel CRC driver genes and, thus, potential drug targets. Here, we define Transmembrane 9 Superfamily 2 (TM9SF2) as a novel CRC oncogene. TM9SF2 is an understudied protein, belonging to a well conserved protein family characterized by their nine putative transmembrane domains. Based on our transposon screen we found that TM9SF2 is a candidate progression driver in digestive tract tumors. Analysis of The Cancer Genome Atlas (TCGA) data revealed that approximately 35% of CRC patients have elevated levels of TM9SF2 mRNA, data we validated using an independent set of CRC samples. RNAi silencing of TM9SF2 reduced CRC cell growth in an anchorage-independent manner, a hallmark of cancer. Furthermore, CRISPR/Cas9 knockout of TM9SF2 substantially diminished CRC tumor fitness in vitro and in vivo. Transcriptome analysis of TM9SF2 knockout cells revealed a potential role for TM9SF2 in cell cycle progression, oxidative phosphorylation, and ceramide signaling. Lastly, we report that increased TM9SF2 expression correlates with disease stage and low TM9SF2 expression correlate with a more favorable relapse-free survival. Taken together, this study provides evidence that TM9SF2 is a novel CRC oncogene.
Insights
Transmembrane 9 Superfamily 2 (TM9SF2) is identified as a novel oncogene driving colorectal cancer (CRC) progression. Targeting TM9SF2 may offer new therapeutic strategies for advanced CRC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Advanced colorectal cancer (CRC) requires novel therapeutic targets.
- The Transmembrane 9 Superfamily (TM9SF) protein family is conserved but understudied.
- Insertional mutagenesis screens can identify novel cancer driver genes.
Purpose of the Study:
- To identify and characterize novel therapeutic targets for advanced colorectal cancer.
- To define the role of Transmembrane 9 Superfamily 2 (TM9SF2) as a potential oncogene in CRC.
Main Methods:
- Conducted an insertional mutagenesis screen in mice to identify CRC driver genes.
- Analyzed The Cancer Genome Atlas (TCGA) and independent CRC patient samples for TM9SF2 expression.
- Utilized RNA interference (RNAi) and CRISPR/Cas9 gene editing to assess TM9SF2 function.
- Performed transcriptome analysis to investigate TM9SF2's molecular pathways.
Main Results:
- TM9SF2 was identified as a novel CRC oncogene and a candidate progression driver.
- Elevated TM9SF2 mRNA levels were found in approximately 35% of CRC patients.
- TM9SF2 silencing or knockout reduced CRC cell growth and tumor fitness in vitro and in vivo.
- TM9SF2 influences cell cycle, oxidative phosphorylation, and ceramide signaling pathways.
- Increased TM9SF2 expression correlates with advanced disease stage and poorer relapse-free survival.
Conclusions:
- TM9SF2 is a novel oncogene that promotes colorectal cancer progression.
- TM9SF2 represents a potential therapeutic target for advanced CRC.
- Further investigation into TM9SF2's role in cancer biology is warranted.
More Related Videos
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
Related Concept Videos
DNA-only Transposons
The donor site from where the transposon is excised is either degraded or...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
In-vitro Mutagenesis
Transposons
Identifying Statistically Significant Differences: The F-Test
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...